Cargando…

Mucosal Healing Did Not Predict Sustained Clinical Remission in Patients with IBD after Discontinuation of One-Year Infliximab Therapy

AIM: To assess the endoscopic activity and Clinical activity after a one-year period of infliximab therapy and to evaluate the association between mucosal healing and need for retreatment after stopping infliximab in patients with Inflammatory bowel disease (IBD). METHODS: The data from 109 patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dai, Cong, Liu, Wei-Xin, Jiang, Min, Sun, Ming-Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203839/ https://www.ncbi.nlm.nih.gov/pubmed/25330148 http://dx.doi.org/10.1371/journal.pone.0110797

Ejemplares similares

Biosimilar infliximab use in paediatric IBD
por: Richmond, Lisa, et al.
Publicado: (2018)

Discontinuation of Scheduled Infliximab in Crohn’s Patients With Clinical Remission: A Retrospective Single-Center Study
por: Hu, Huiqin, et al.
Publicado: (2017)

Infliximab trough levels are associated with endoscopic healing but not with transmural healing at one year treatment with infliximab in pediatric patients with Crohn’s disease
por: Choi, So Yoon, et al.
Publicado: (2023)

Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial
por: Tanaka, Yoshiya, et al.
Publicado: (2020)

Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial
por: Buhl, Sine Schnoor, et al.
Publicado: (2014)

Remission induction by Raising the dose of Remicade in RA (RRRR) study: Rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritis
por: Oba, Koji, et al.
Publicado: (2017)

Infliximab in young paediatric IBD patients: it is all about the dosing
por: Jongsma, Maria M. E., et al.
Publicado: (2020)

Active postoperative acromegaly: sustained remission after discontinuation of somatostatin analogues
por: Alvarez-Escola, Cristina, et al.
Publicado: (2016)

Allopurinol in combination with thiopurine induces mucosal healing and improves clinical and metabolic outcomes in IBD
por: Moreau, Brigitte, et al.
Publicado: (2017)

Intestinal Mucosal Wound Healing and Barrier Integrity in IBD–Crosstalk and Trafficking of Cellular Players
por: Sommer, Katrin, et al.
Publicado: (2021)

Infliximab Preferentially Induces Clinical Remission and Mucosal Healing in Short Course Crohn's Disease with Luminal Lesions through Balancing Abnormal Immune Response in Gut Mucosa
por: Yu, Lijuan, et al.
Publicado: (2015)

Are EPA and DHA Derivatives Involved in IBD Remission?
por: Kikut, Justyna, et al.
Publicado: (2022)

Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study
por: Tanaka, Y, et al.
Publicado: (2010)

Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial
por: Stamm, Tanja Alexandra, et al.
Publicado: (2018)

Sustained clinical remission under infliximab/rituximab combination therapy in a patient with granulomatosis with polyangiitis
por: Valor-Méndez, Larissa, et al.
Publicado: (2021)

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
por: Fitzgerald, Timothy, et al.
Publicado: (2021)

Infliximab for medical induction of remission in Crohn's disease
por: Gordon, Morris, et al.
Publicado: (2023)

Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy
por: Huang, Vivian W., et al.
Publicado: (2015)

Mucosal microbiota and gene expression are associated with long-term remission after discontinuation of adalimumab in ulcerative colitis
por: Sakurai, Toshiharu, et al.
Publicado: (2020)

Efficacy of infliximab treatment on the mucosal healing of different intestinal segments in patients with ileocolonic Crohn’s disease
por: Wu, Yaling, et al.
Publicado: (2020)

SUN-383 Sustained Clinical Improvement after Discontinuation of Mifepristone: Unexpected Remission of Hypercortisolism
por: Anderson, Robin, et al.
Publicado: (2019)

Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease
por: Gelbenegger, Georg, et al.
Publicado: (2022)

Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study
por: Huizinga, T W J, et al.
Publicado: (2015)

Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study
por: Koga, Akihiro, et al.
Publicado: (2018)

Remission of Cap Polyposis Maintained for More Than Three Years after Infliximab Treatment
por: Kim, Eun Sun, et al.
Publicado: (2009)

COVID-19—from mucosal immunology to IBD patients
por: Weidinger, Carl, et al.
Publicado: (2021)

Association of sleep quality and mucosal healing in patients with inflammatory bowel disease in clinical remission
por: Michalopoulos, George, et al.
Publicado: (2018)

Efficiency of Orexin-A for Inflammatory Flare and Mucosal Healing in Experimental Colitis: Comparison with the Anti-TNF Alpha Infliximab
por: Blais, Anne, et al.
Publicado: (2023)

Remission of Refractory Celiac Disease With Infliximab in a Pediatric Patient
por: Rawal, Nidhi, et al.
Publicado: (2015)

Low-FODMAP Diet for the Management of Irritable Bowel Syndrome in Remission of IBD
por: Więcek, Martyna, et al.
Publicado: (2022)

Successful Discontinuation of Infliximab in a Refractory Case of Vasculo-Behçet Disease
por: Nakamura, Akihiro, et al.
Publicado: (2016)

High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study
por: Wilson, Aze, et al.
Publicado: (2021)

Antibody responses to SARS-CoV-2 infection are attenuated in infliximab-treated patients with IBD
por: Ray, Katrina
Publicado: (2021)

Higher Adalimumab Trough Levels Are Associated with Histologic Remission and Mucosal Healing in Inflammatory Bowel Disease
por: Wong, Rochelle, et al.
Publicado: (2023)

PeerWise and Pathology: Discontinuing a teaching innovation that did not achieve its potential
por: Smith, Christopher Dimick, et al.
Publicado: (2020)

Association between Fecal Calprotectin and Mucosal Healing in Pediatric Patients with Crohn’s Disease Who Have Achieved Sustained Clinical Remission with Anti-Tumor Necrosis Factor Agents
por: Lee, Yoo Min, et al.
Publicado: (2022)

One-year infliximab administration for the treatment of chronic refractory pouchitis
por: Viazis, Nikos, et al.
Publicado: (2011)

Discontinuation of Azathioprine could be considered in pediatric patients with Crohn’s disease who have sustained clinical and deep remission
por: Jeong, Tae Jong, et al.
Publicado: (2022)

Sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis (XANADU study): an open-label randomised study
por: Kubo, Satoshi, et al.
Publicado: (2023)

Prostaglandin E‐major urinary metabolite diagnoses mucosal healing in patients with ulcerative colitis in remission phase
por: Sakurai, Toshiyuki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9s2mmfksmg79goeb77drf0gebe